197 related articles for article (PubMed ID: 29314171)
41. RETINAL PIGMENT EPITHELIUM UNDULATIONS IN ACUTE STAGE OF VOGT-KOYANAGI-HARADA DISEASE: Biomarker for Functional Outcomes After High-Dose Steroid Therapy.
Hashizume K; Imamura Y; Fujiwara T; Machida S; Ishida M; Kurosaka D
Retina; 2016 Feb; 36(2):415-21. PubMed ID: 26352553
[TBL] [Abstract][Full Text] [Related]
42. Enhanced depth imaging optical coherence tomography of the choroid in Vogt-Koyanagi-Harada disease.
Nakayama M; Keino H; Okada AA; Watanabe T; Taki W; Inoue M; Hirakata A
Retina; 2012; 32(10):2061-9. PubMed ID: 23095726
[TBL] [Abstract][Full Text] [Related]
43. Vogt-Koyanagi-Harada Disease and Systemic Lupus Erythematosus Occurring during Adalimumab Therapy for Ulcerative Colitis.
AlBloushi AF; Al-Hadlaq OS; AlRashed FA; Abu El-Asrar AM
Middle East Afr J Ophthalmol; 2020; 27(3):185-187. PubMed ID: 33488017
[TBL] [Abstract][Full Text] [Related]
44. A Case of Perforating Folliculitis Induced by Vemurafenib.
Shiraishi K; Masunaga T; Tohyama M; Sayama K
Acta Derm Venereol; 2019 Feb; 99(2):230-231. PubMed ID: 30281138
[No Abstract] [Full Text] [Related]
45. [Disc neovascularization in a patient with Vogt-Koyanagi-Harada disease and efficacy of steroid pulse therapy].
Kawaguchi T; Yokota M; Sugita S; Mochizuki M
Nippon Ganka Gakkai Zasshi; 2006 Jan; 110(1):58-60. PubMed ID: 16491875
[TBL] [Abstract][Full Text] [Related]
46. Usefulness of anterior chamber depth measurement for efficacy assessment of steroid pulse therapy in patients with Vogt-Koyanagi-Harada disease.
Otsuki T; Shimizu K; Igarashi A; Kamiya K
Jpn J Ophthalmol; 2010 Sep; 54(5):396-400. PubMed ID: 21052900
[TBL] [Abstract][Full Text] [Related]
47. Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine.
Koong LR; Chee WK; Toh ZH; Ng XL; Agrawal R; Ho SL
Ocul Immunol Inflamm; 2021 Aug; 29(6):1212-1215. PubMed ID: 34505819
[TBL] [Abstract][Full Text] [Related]
48. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
49. [Vogt-Koyanagi-Harada syndrome: angiographic and optical coherence tomography correlations].
Wolff B; Masse H; Bonnel S; Sahel JA; Metge F
J Fr Ophtalmol; 2009 Oct; 32(8):610-1. PubMed ID: 19733420
[No Abstract] [Full Text] [Related]
50. Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada Disease Presenting 3 Months Following Discontinuation of Nivolumab.
Tieger MG; Eliott D; Cakir B; Dahrouj M
Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):183-187. PubMed ID: 36944065
[TBL] [Abstract][Full Text] [Related]
51. Reaccion acneiforme noduloquistica secundaria a vemurafenib con buena respuesta a isotretinoina oralSevere acneiform eruption associated with vemurafenib with response to isotretinoin.
Elosua-Gonzalez M; Lopez-Estebaranz JL; Garcia-Zamora E; Vela-Ganuza M; Rodrigez-Vasquez X
Dermatol Online J; 2018 Aug; 24(8):. PubMed ID: 30677858
[TBL] [Abstract][Full Text] [Related]
52. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
53. Subfoveal choroidal thickness after treatment of Vogt-Koyanagi-Harada disease.
Maruko I; Iida T; Sugano Y; Oyamada H; Sekiryu T; Fujiwara T; Spaide RF
Retina; 2011 Mar; 31(3):510-7. PubMed ID: 20948460
[TBL] [Abstract][Full Text] [Related]
54. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
55. [Severe panuveitis in a metastatic cutaneous melanoma patient treated with vemurafenib].
Boiché M; Conart JB; Angioi-Duprez K
J Fr Ophtalmol; 2018 Jun; 41(6):e291-e292. PubMed ID: 29908650
[No Abstract] [Full Text] [Related]
56. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
57. [A case of the Vogt-Koyanagi-Harada syndrome].
Peyresblanques J; Saint Val C; Collin JP
Bull Soc Ophtalmol Fr; 1984; 84(6-7):827-30. PubMed ID: 6534621
[No Abstract] [Full Text] [Related]
58. Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy.
Godse R; Mcgettigan S; Schuchter LM; Ellebrecht CT; Chu EY
Clin Exp Dermatol; 2021 Aug; 46(6):1111-1112. PubMed ID: 33846999
[No Abstract] [Full Text] [Related]
59. Vogt-Kayanagi-Harada-Like Uveitis Induced by Dabrafenib/Trametinib Therapy for Cutaneous Malignant Melanoma.
Kaymak NZ; Kaplan AT
Ophthalmic Surg Lasers Imaging Retina; 2023 Aug; 54(8):477-480. PubMed ID: 37535619
[TBL] [Abstract][Full Text] [Related]
60. Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
Ushio R; Yamamoto M; Miyasaka A; Muraoka T; Kanaoka H; Tamura H; Kaneko A; Izawa A; Hirama N; Teranishi S; Manabe S; Inoue T; Shibata K; Sugiura Y; Kudo M; Kaneko T
Intern Med; 2021 Nov; 60(22):3593-3598. PubMed ID: 34092725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
